Hisamitsu To Apply For Additional Indication Of Fentos Tape For Chronic Pain Treatment
This article was originally published in PharmAsia News
Hisamitsu Pharmaceuticals plans to file an application for the additional indication of its transdermal, long-acting cancer pain relief patch Fentos Tape (fentanyl citrate) for chronic pain sometime this year.
You may also be interested in...ï»¿
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.
Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.
Nearly 500 shipments of illegal and unapproved prescription drugs and combination medical devices were seized at US borders thanks to Operation Broadsword.